title: Myocardial infarction during intravenous immunoglobulin infusion in a 65-year-old man with common variable immunodeficiency and subsequent successful repeated administration.
abstract: BACKGROUND
  Intravenous immunoglobulin (IVIG) may cause thromboembolic events. Although such events are usually associated with large IVIG doses administered to treat neurologic diseases, thromboembolic events may also occur with standard immunodeficiency doses.
  
  
  OBJECTIVE
  We describe a 65-year-old man with common variable immunodeficiency (CVID) who experienced angina and myocardial infarction with IVIG infusion.
  
  
  METHODS
  The patient's electronic medical record was reviewed.
  
  
  RESULTS
  The patient developed substernal chest pain during a scheduled 40-g (400-mg/kg) infusion. The infusion was discontinued, and a cardiac evaluation was initiated. The patient was found to have elevated troponin T and creatine kinase MB levels, signifying cardiac injury. Heart catheterization revealed severe vessel disease, and surgical revascularization was subsequently performed. Three weeks after revascularization, an IVIG dose of 200 mg/kg was cautiously readministered. This dose was increased in 2 weeks to 300 mg/kg, which was tolerated every 3 to 4 weeks without any adverse thrombotic events in the subsequent 12 months.
  
  
  CONCLUSIONS
  This case demonstrates not only angina and myocardial infarction associated with IVIG infusion in a patient with CVID but also the successful reinitiation of IVIG infusion after surgical revascularization. This case also underscores the importance of caution with IVIG infusion in patients with CVIDand known coronary artery disease.
authors.affiliation: Division of Allergic Diseases, Department of Medicine. Mayo Clinic, Rochester, Minnesota 55905, USA. dave.shoban@mayo.edu
authors.forename: Shoban
authors.initials: S
authors.lastname: Davé
authors.forename: John
authors.initials: J
authors.lastname: Hagan
mesh_terms: D000368:Aged; D017074:Common Variable Immunodeficiency / Q000628:therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000628:therapy; D009204:Myocardial Revascularization
chemical_list: D016756:Immunoglobulins, Intravenous